Haloperidol in the Acute Treatment of Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

Honkaniemi, Jari; Liimatainen, Suvi; Rainesalo, Sirpa; Sulavuori, Sari

doi:10.1111/j.1526-4610.2006.00438.x

Cited by 71 publications

(79 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As lisuride is an extremely potent 5-HT 2B receptor antagonist (Hofmann et al 2006), it is reasonable to assume that the antimigraine action of this drug could be mediated, at least partly, via blockade of 5-HT 2B receptors. More recently, haloperidol, which blocks D 1 , D 2 , 5-HT 2 , H 1 , and α 2 -adrenergic receptors in the brain, was reported to be effective in the acute treatment of migraine in a randomized, double-blind, placebo-controlled study, although the majority of patients suffered from side effects (Honkaniemi et al 2006). Dopamine causes vasoconstriction in rat dural arteries, but this effect is most likely mediated by α 2 -adrenoceptors and not dopamine receptors (Akerman and Goadsby 2005).…”

Section: Dopamine Receptorsmentioning

confidence: 99%

Current and prospective pharmacological targets in relation to antimigraine action

Mehrotra

Gupta

Chan

et al. 2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

Migraine is a recurrent incapacitating neurovascular disorder characterized by unilateral and throbbing headaches associated with photophobia, phonophobia, nausea, and vomiting. Current specific drugs used in the acute treatment of migraine interact with vascular receptors, a fact that has raised concerns about their cardiovascular safety. In the past, α-adrenoceptor agonists (ergotamine, dihydroergotamine, isometheptene) were used. The last two decades have witnessed the advent of 5-HT 1B/1D receptor agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute treatment of migraine. Moreover, current prophylactic treatments of migraine include 5-HT 2 receptor antagonists, Ca 2+ channel blockers, and β-adrenoceptor antagonists. Despite the progress in migraine research and in view of its complex etiology, this disease still remains underdiagnosed, and available therapies are underused. In this review, we have discussed pharmacological targets in migraine, with special emphasis on compounds acting on 5-HT (5-HT 1-7 ), adrenergic (α 1 , α 2, and β), calcitonin gene-related peptide (CGRP 1 and CGRP 2 ), adenosine (A 1 , A 2 , and A 3 ), glutamate (NMDA, AMPA, kainate, and metabotropic), dopamine, endothelin, and female hormone (estrogen and progesterone) receptors. In addition, we have considered some other targets, including gamma-aminobutyric acid, angiotensin, bradykinin, histamine, and ionotropic receptors, in relation to antimigraine therapy. Finally, the cardiovascular safety of current and prospective antimigraine therapies is touched upon.

show abstract

Section: Dopamine Receptorsmentioning

confidence: 99%

Current and prospective pharmacological targets in relation to antimigraine action

Mehrotra

Gupta

Chan

et al. 2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…Three studies reported proportions of patients with subjective headache relief 1 to 3 hours post administration of a butyrophenone compared to placebo or meperidine in the treatment of migraine. [13][14][15] The weighted average rate of subjective headache relief 1 to 3 hours after treatment by a butyrophenone in these three trials was 82.8% (n 5 216).…”

Section: Resultsmentioning

confidence: 92%

“…Two of these studies compared a butyrophenone to placebo in the treatment of migraine. 13,14 One compared intravenous (IV) haloperidol to placebo, 13 whereas the other compared intramuscular (IM) droperidol to placebo using four different dosage regimens. 14 The remaining four studies compared parenteral droperidol to a comparator drug in the treatment of migraine or benign headache.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Are butyrophenones effective for the treatment of primary headache in the emergency department?

Leong

Kelly

2011

CJEM

View full text Add to dashboard Cite

Objectives: Butyrophenones have been reported to provide effective migraine relief in the emergency department (ED). We conducted a systematic review of the evidence for their use in the ED. Data source: We searched the Cochrane, Medline, Embase, and CINAHL databases. Study selection: Included studies were randomized trials of a parenteral butyrophenone (droperidol, haloperidol) versus placebo or a comparator in migraine or benign headache with results available in English. Study quality was determined using the Jadad score. Six articles were included. Data extraction: Primary outcomes were subjective or objective headache relief (. 50% improvement in visual analogue scale scores). Secondary outcomes included side effects. We reported pooled odds ratios (ORs) with their 95% confidence intervals (CIs) for subjective or objective headache relief for butyrophenones versus placebo or comparator agents. Data synthesis: Three studies reported subjective headache relief with a butyrophenone versus placebo or meperidine in migraine. Two studies reported objective headache relief with droperidol versus prochlorperazine, whereas one study compared droperidol versus olanzapine in benign headache. The pooled OR for subjective headache relief was 8.08 (95% CI 1.54-42.30) for a butyrophenone versus placebo, whereas it was 1.50 (95% CI 0.33-6.77) for droperidol versus meperidine in migraine. The pooled OR for objective headache relief was 2.96 (95% CI 1.36-6.43) for droperidol versus prochlorperazine in benign headache. Rates of side effects were 10 to 45%; akathesia and sedation were the most common. Conclusions: Butyrophenones are effective for the relief of migraine or benign headache. However, adverse effects make it difficult to recommend butyrophenones above agents with similar effectiveness and fewer problems. RÉ SUMÉObjectif : Il a é té signalé que les butyrophé nones soulageaient les migraines dans les services d'urgence. Nous avons procé dé à une analyse systé matique sur leur utilisation à l'urgence. Source des donné es : Nous avons interrogé les bases de donné es Cochrane, Medline, Embase et CINAHL. Sé lection des é tudes : Nous avons retenu les essais randomisé s d'un butyrophé none parenté ral (dropé ridol, halopé ridol) contre un placebo ou un comparateur en cas de migraine ou de cé phalé e bé nigne. Les ré sultats devaient ê tre disponibles en anglais. Nous avons é valué la qualité des essais selon le score de Jadad. Six articles ont é té retenus. Extraction des donné es : Les principaux critè res d'é valuation é taient le soulagement subjectif ou objectif de maux de tê te (. 50 % d'amé lioration selon l'é chelle visuelle analogique). Les critè res secondaires d'é valuation é taient entre autres les effets secondaires. Nous avons inclus les rapports de cotes combiné s (RC) avec intervalle de confiance à 95 % (IC) pour le soulagement subjectif ou objectif de maux de tê te pour le groupe butyrophé nones par rapport au groupe placebo ou autres comparateurs. Synthè se des donné es : Trois é tudes ont signal...

show abstract

“…Intravenous droperidol [58,59] is effective in status migranosus and more effective than placebo in controlled trials for acute migraine. Multiple studies also support the use of chlorpromazine [60,61], haloperidol [62], and metoclopramide [63,64] with or in conjunction with DHE treatment. EKG monitoring is recommended for drugs which may prolong QT interval.…”

mentioning

confidence: 99%

Inpatient Management of Migraine

Marmura

Goldberg

2015

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Haloperidol in the Acute Treatment of Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

Cited by 71 publications

References 24 publications

Current and prospective pharmacological targets in relation to antimigraine action

Current and prospective pharmacological targets in relation to antimigraine action

Are butyrophenones effective for the treatment of primary headache in the emergency department?

Inpatient Management of Migraine

Contact Info

Product

Resources

About